
Elite Pharmaceuticals Inc
OTC:ELTP

Intrinsic Value
The intrinsic value of one
ELTP
stock under the Base Case scenario is
0.2767
USD.
Compared to the current market price of 0.5601 USD,
Elite Pharmaceuticals Inc
is
Overvalued by 51%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Elite Pharmaceuticals Inc
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Elite Pharmaceuticals Inc
Balance Sheet Decomposition
Elite Pharmaceuticals Inc
Current Assets | 57.7m |
Cash & Short-Term Investments | 11.3m |
Receivables | 29.2m |
Other Current Assets | 17.2m |
Non-Current Assets | 38.6m |
Long-Term Investments | 92k |
PP&E | 14.1m |
Intangibles | 5.6m |
Other Non-Current Assets | 18.8m |
Free Cash Flow Analysis
Elite Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Elite Pharmaceuticals Inc
Revenue
|
84m
USD
|
Cost of Revenue
|
-44m
USD
|
Gross Profit
|
40.1m
USD
|
Operating Expenses
|
-18.9m
USD
|
Operating Income
|
21.2m
USD
|
Other Expenses
|
-25.5m
USD
|
Net Income
|
-4.3m
USD
|
ELTP Profitability Score
Profitability Due Diligence
Elite Pharmaceuticals Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.

Score
Elite Pharmaceuticals Inc's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
ELTP Solvency Score
Solvency Due Diligence
Elite Pharmaceuticals Inc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.

Score
Elite Pharmaceuticals Inc's solvency score is 89/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ELTP Price Targets Summary
Elite Pharmaceuticals Inc
Dividends
Current shareholder yield for ELTP is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ELTP
stock under the Base Case scenario is
0.2767
USD.
Compared to the current market price of 0.5601 USD,
Elite Pharmaceuticals Inc
is
Overvalued by 51%.